The clinical forms and the treatment of status epilepticus;Klinik und therapie des konvulsiven status epilepticus

Klinische Neurophysiologie

Volumn 43, Issue 2, 2012, Pages 144-150

  Trinka, E ^a  

^a Christian Doppler Klinik   (Austria)

Author keywords

Acute seizures; Intravenous antiepilept therapy; Status epilepticus

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; FOSPHENYTOIN SODIUM; LEVETIRACETAM; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PROPOFOL; THIOPENTAL; VALPROIC ACID;

ARTICLE; CLINICAL FEATURE; EPILEPTIC STATE; HUMAN; MORTALITY; TONIC CLONIC SEIZURE;

EID: 84862618001     PISSN: 14340275     EISSN: 14394081     Source Type: Journal    
DOI: 10.1055/s-0032-1314862     Document Type: Article

References (99)

1. Wilson JV, Reynolds EH. Texts and documents. Translation and analysis of a cuneiform text forming part of a Babylonian treatise on epilepsy. Med Hist 1990;34:185-198
2. Temkin O. The falling sickness: a history of epilepsy from the Greeks to the beginnings. London and Baltimore: Johns Hopkins Press; 1971
3. Wolf P, Trinka E, Bauer G. Absence status epilepticus: The first documented case? Epilepsia 2007;48:4-5
4. Clark LP, Prout TP. Status epilepticus: a clinical and pathological study in epilepsy [part1]. American Journal of Insanity 1903;60:291-306
5. Clark LP, Prout TP. Status epilepticus: a clinical and pathological study in epilepsy [part 2]. American Journal of Insanity 1903;60:645-675
6. Clark LP, Prout TP. Status epilepticus: a clinical and pathological study in epilepsy [part 3]. American Journal of Insanity 1904;61:81-108
7. Shorvon S, Trinka E. Status epilepticus - making progress. Epilepsia 2011;52(Suppl 8):1-2
8. Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia 2011;52(Suppl 8):53-56
9. Kalita J, Misra UK, Patel R. Initial EEG in status epilepticus is helpful in predicting seizure recurrence. Electromyogr Clin Neurophysiol 2006;46:139-144
10. Pandian JD, Cascino GD, So EL et al. Digital video-electroencephalographic monitoring in the neurological-neurosurgical intensive care unit: clinical features and outcome. Arch Neurol 2004;61:1090-1094
11. Claassen J, Hirsch LJ, Emerson RG et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001;57:1036-1042
12. Hirsch LJ. Continuous EEG monitoring in the intensive care unit: an overview. J Clin Neurophysiol 2004;21:332-340
13. Hirsch LJ. Brain monitoring: the next frontier of ICU monitoring. J Clin Neurophysiol 2004;21:305-306
14. Hirsch LJ, Kull LL. Continuous EEG monitoring in the intensive care unit. Am J Electroneurodiagnostic Technol 2004;44:137-158
15. Jette N, Hirsch LJ. Continuous electroencephalogram monitoring in critically ill patients. Curr Neurol Neurosci Rep 2005;5:312-21
16. Wittman JJ Jr, Hirsch LJ. Continuous electroencephalogram monitoring in the critically ill. Neurocrit Care 2005;2:330-341
17. Jaitly R, Sgro JA, Towne AR et al. Prognostic value of EEG monitoring after status epilepticus: a prospective adult study. J Clin Neurophysiol 1997;14:326-334
18. Feddersen B, Trinka E. Status epilepticus. Nervenarzt 2012
19. Amzica F, Kroeger D. Cellular mechanisms underlying EEG waveforms during coma. Epilepsia 2011;52(Suppl 8):25-27
20. Amzica F. Basic physiology of burst-suppression. Epilepsia 2009;50(Suppl 12):38-39
21. Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia 1999;40:759-762
22. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005;62:1698-1702
23. Shorvon S, Trinka E, Walker M. First London Colloquium on Status Epilepticus. Epilepsia 2007;48:1-3
24. Trinka E, Shorvon S. The proceedings of the Innsbruck Colloquium on Status Epilepticus. Epilepsia 2009;50(Suppl 12):1-2
25. Cock HR. Established status epilepticus treatment trial (ESETT). Epilepsia 2011;52(Suppl 8):50-52
26. Shorvon S, Baulac M, Cross H et al. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 2008;49:1277-1285
27. Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993;43:483-488
28. Trinka E. Benzodiazepines used primarily for emergency treatment (Diazepam, Lorazepam, and Midazolam). In: Shorvon S D, Perucca E, Engel J Jr (eds.). Treatment of Epilepsies. Oxford: Blackwell Publishing; 2009;470-484
29. Treiman DM, Meyers PD, Walton NY et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Aff airs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;339:792-798
30. Leppik IE, Derivan AT, Homan RW et al. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983;249:1452-1454
31. Alldredge BK, Gelb AM, Isaacs SM et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001;345:631-637
32. Prasad K, Krishnan PR, Al Roomi K et al. Anticonvulsant therapy for status epilepticus. Br J Clin Pharmacol 2007;63:640-647
33. Meierkord H, Boon P, Engelsen B et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006;13:445-450
34. Dreifuss FE, Rosman NP, Cloyd JC et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998;338:1869-1875
35. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999;353:623-626
36. McIntyre J, Robertson S, Norris E et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005;366:205-210
37. Mpimbaza A, Ndeezi G, Staedke S et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics 2008;121:e58-e64
38. Baysun S, Aydin OF, Atmaca E et al. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila) 2005;44:771-776
39. Lahat E, Goldman M, Barr J et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ 2000;321:83-86
40. Fisgin T, Gurer Y, Tez ic T et al. E ff ects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol 2002;17:123-126
41. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol 2006;34:355-359
42. Silbergleit R, Durkalski V, Lowenstein D et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012;366:591-600
43. Silbergleit R, Lowenstein D, Durkalski V et al. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia 2011;52(Suppl 8):45-47
44. Trinka E, Dobesberger J. New Treatment Options in Status Epilepticus: a critical review on levetiracetam. Therap Adv Neurol Dis 2009;2:79-91
45. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia 2011;52(Suppl 8):35-38
46. Wilder BJ, Ramsay RE, Willmore LJ et al. E fficacy of intravenous phenytoin in the treatment of status epilepticus: kinetics of central nervous system penetration. Ann Neurol 1977;1:511-518
47. Cranford RE, Leppik IE, Patrick B et al. Intravenous phenytoin in acute treatment of seizures. Neurology 1979;29:1474-1479
48. Leppik IE, Patrick BK, Cranford RE. Treatment of acute seizures and status epilepticus with intravenous phenytoin. Adv Neurol 1983;34:447-451
49. Burneo JG, Anandan JV, Barkley GL. A prospective study of the incidence of the purple glove syndrome. Epilepsia 2001;42:1156-1159
50. O'Brien TJ, Cascino GD, So EL et al. Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin. Neurology 1998;51:1034-1039
51. Knapp LE, Kugler AR. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. J Child Neurol 1998;13(Suppl 1):S15-S18
52. Wilder BJ, Campbell K, Ramsay RE et al. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neurol 1996;53:764-768
53. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998;338:970-976
54. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714
55. Zaccara G, Franciotta D, Perucca E. Idiosyncratic Adverse Reactions to Antiepileptic Drugs. Epilepsia 2007
56. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancyrelated issues. Drug Saf 2006;29:1-21
57. Gerstner T, Busing D, Bell N et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007;42:39-48
58. Konig SA, Schenk M, Sick C et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 1999;40:1036-1040
59. Konig SA, Siemes H, Blaker F et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994;35:1005-1015
60. Hussein Z, Mukherjee D, Lamm J et al. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J Clin Pharmacol 1994;34:754-759
61. Hussein Z, Patterson KJ, Lamm JE et al. E ff ect of infusion duration on valproate pharmacokinetics. Biopharm Drug Dispos 1993;14:389-399
62. Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999;35:147-153
63. Wheless JW, Vazquez BR, Kanner AM et al. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004;63:1507-1508
64. Naritoku DK, Mueed S. Intravenous loading of valproate for epilepsy. Clin Neuropharmacol 1999;22:102-106
65. Ramsay RE, Cantrell D, Collins SD et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. Epilepsy Res 2003;52:189-201
66. Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000;55:722-724
67. Honack D, Loscher W. Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res 1992;13:215-221
68. Walton NY, Treiman DM. Valproic acid treatment of experimental status epilepticus. Epilepsy Res 1992;12:199-205
69. Limdi NA, Shimpi AV, Faught E et al. E fficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005;64:353-355
70. Limdi NA, Faught E. The safety of rapid valproic acid infusion. Epilepsia 2000;41:1342-1345
71. Kramer G, Bergmann A, Deshpande LS et al. Current Place of Intravenous Valproic Acid in the Treatment of Generalized Tonic-Clonic Status Epilepticus. Aktuelle Neurologie 2005;32(5):263-274 Ref Type: Journal (Full)
72. Limdi NA, Knowlton RK, Cofield SS et al. Safety of rapid intravenous loading of valproate. Epilepsia 2007;48:478-483
73. Teich M, Longin E, Dempfle CE et al. Factor XIII deficiency associated with valproate treatment. Epilepsia 2004;45:187-189
74. Beenen LF, Lindeboom J, Kasteleijn-Nolst Trenite DG et al. Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J Neurol Neurosurg Psychiatry 1999;67:474-480
75. Ward MM, Barbaro NM, Laxer KD et al. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 1996;37:98-101
76. Anderson GD, Lin YX, Berge C et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997;87:252-256
77. Andersen V, Sonne J, Andersen M. Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur J Clin Pharmacol 2001;57:517-521
78. Embacher N, Karner E, Wanschitz J et al. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. Eur J Neurol 2006;13:e5-e6
79. Scheffner D, Konig S, Rauterberg-Ruland I et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29:530-542
80. Otoul C, Arrigo C, van Rijckevorsel K et al. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28:72-78
81. Gidal BE, Baltes E, Otoul C et al. E ff ect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res 2005;64:1-11
82. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43:707-724
83. Mazarati AM, Baldwin R, Klitgaard H et al. Anticonvulsant eff ects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 2004;58:167-174
84. Shaner DM, McCurdy SA, Herring MO et al. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988;38:202-207
85. Ben Menachem E, Biton V, Jatuzis D et al. E fficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-1317
86. Krauss G, Ben-Menachem E, Mameniskiene R et al. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 2010;51:951-957
87. Biton V, Rosenfeld WE, Whitesides J et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008;49:418-424
88. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009;14:429-431
89. Mayer SA, Claassen J, Lokin J et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002;59:205-210
90. Holtkamp M, Othman J, Buchheim K et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005;76:534-539
91. Kalviainen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus: a guide to treatment. CNS Drugs 2005;19:759-768
92. Rossetti AO. Which anaesthetic should be used in the treatment of refractory status epilepticus? Epilepsia 2007 Ref Type: In Press
93. Holtkamp M. The anaesthetic and intensive care of status epilepticus. Curr Opin Neurol 2007;20:188-193
94. Claassen J, Hirsch LJ, Emerson RG et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002;43:146-153
95. Niermeijer JM, Uiterwaal CS, Van Donselaar CA. Propofol in status epilepticus: little evidence, many dangers? J Neurol 2003;250:1237-1240
96. Vasile B, Rasulo F, Candiani A et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003;29:1417-1425
97. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;134:2802-2818
98. Walker MC, Howard RS, Smith SJ et al. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. QJM 1996;89:913-920
99. Holtkamp M, Othman J, Buchheim K et al. Diagnosis of psychogenic nonepileptic status epilepticus in the emergency setting. Neurology 2006;66:1727-1729